![[Toyota Times] Century as a Brand, Lexus as Innovation: All the Details on Toyota's New Project!](https://businessfortnight.com/wp-content/uploads/2025/10/Toyota-Times-Century-as-a-Brand-Lexus-as-Innovation-All-218x150.jpg "[Toyota Times] Century as a Brand, Lexus as Innovation: All the Details on Toyota's New Project!")
Debiopharm Innovation Fund strategically invests in Whitelab Genomics’ mission to make genomic drugs improvement quicker and leaner for extra environment friendly entry to most cancers sufferers in the future
LAUSANNE, Switzerland, Sept. 13, 2022 /PRNewswire/ — Debiopharm Innovation Fund, the strategic funding arm of Swiss biopharmaceutical firm Debiopharm (www.Debiopharm.com), introduced as we speak their funding in Whitelab Genomics alongside French Venture Capital firm, Omnes Capital, in a $10 Million Series A Round to advance their mission to speed up the improvement of genomics medicines by way of expertise powered by synthetic intelligence (AI). Whitelab Genomics’ computational platform reduces biotherapies’ improvement time and price, enabling quicker entry to the market and cheaper therapeutic options out there for sufferers in want. Debiopharm’s funding in Whitelabs Genomics contributes to the development plan of the start-up’ R&D staff and US operations. Such an funding aligns with Debiopharm’s deal with investing in digital well being options that enhance the most cancers affected person journey, remodel pharmaceutical R&D, and shift healthcare in direction of a extra patient-centric strategy.
Founded in 2019 by David Del Bourgo, MBA, and Julien Cottineau, Ph.D., alongside a staff of world-class information scientists specialised in AI, computational biologists, molecular biologists, and genomic drugs scientists, the start-up gives in-silico simulations personalized for goal discovery, vector, and payload design, genotoxicity evaluation and identification of experimental protocols of in vitro and in vivo methods.
“We’re moving into a time where AI-based technology will play a critical role in drug development. With better ways to develop drugs, de-risk assets, de-risk any toxicity, and ensure efficacy, we’re able to bring more personalized drugs to patients – that’s precisely what Whitelab Genomics is proven to do,” said Tanja Dowe, CEO of the Debiopharm Innovation Fund.
“The value of using this AI-based platform is the potential acceleration of pre-clinical, translational stage, helping drug research companies quickly design payloads and vectors and identify the best experimental protocols for in vitro and in vivo tests,” mentioned Hamzeh Abdul-Hadi, Investment Director of the Debiopharm Innovation Fund.
“We are very excited to close this first institutional investment round with such renowned investors with deep knowledge of the pharma environment. With this funding, we can continue developing our proprietary data sets and algorithms for both payload and vectors, and develop our collaborations with our customers,” expressed David Del Bourgo, CEO and co-founder of Whitelab Genomics.
About Whitelab Genomics
WhiteLab Genomics, primarily based in Paris and Cambridge (MA) was based in 2019 by David Del Bourgo and Julien Cottineau, consultants in genomics drug improvement and commercialization. WhiteLab Genomics goals to revolutionize genomic therapies improvement utilizing private and non-private information and in-house AI algorithms. Whitelab Genomics helps its shoppers through the in-silico improvement phases enabling them to rapidly develop goal vectors and payloads and save valuable time wanted to give sufferers entry to new genomic therapies. In solely 2 years, Whitelab Genomics has satisfied main European and US Biotech and pharma to use its options for his or her new drug improvement applications, together with RNA, DNA & Cell therapies. WhiteLab Genomics can also be collaborating with world-renowned INSERM and Genethon laboratories and has been chosen by Y-Combinator in its Winter 2022 batch. The firm has received a number of awards, together with the Galien Foundation nominee for startups, the Alumni New Venture Fund from the Polsky Innovation Center at the University of Chicago, and the Future 40 from Station F.
For extra data, please go to www.whitelabgx.com
About Debiopharm Innovation Fund
Debiopharm Innovation Fund, the strategic funding arm of Swiss biopharmaceutical firm Debiopharm, gives strategic funding and steering for firms with an ambition to enhance the affected person journey, re-imagine how scientific trials are performed, together with firms providing digital platforms that help cutting-edge drug applied sciences. Since 2017 Debiopharm has invested in 14 digital well being firms, usually main the funding rounds.
For extra data, please go to www.debiopharm.com/digital-health/
We are on Twitter. Follow us @DebiopharmNews at http://twitter.com/DebiopharmNews
Debiopharm Contact
Dawn Bonine
Head of Communications
[email protected]
Tel: +41 (0)21 321 01 11
